Coronary heart disease outcomes in patients receiving antidiabetic agents
Article first published online: 6 JUN 2007
Copyright © 2007 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 16, Issue 7, pages 711–725, July 2007
How to Cite
McAfee, A. T., Koro, C., Landon, J., Ziyadeh, N. and Walker, A. M. (2007), Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidem. Drug Safe., 16: 711–725. doi: 10.1002/pds.1443
- Issue published online: 28 JUN 2007
- Article first published online: 6 JUN 2007
- Manuscript Accepted: 1 JUN 2007
- Manuscript Revised: 31 MAY 2007
- Manuscript Received: 26 FEB 2007
- i3 Drug Safety and GlaxoSmithKline
- myocardial infarction;
- coronary revascularization;
- retrospective cohort study;
- propensity score matching
There is conflicting evidence on the reduction of cardiovascular risk in diabetic patients treated with oral antidiabetic agents.
To compare the risk of myocardial infarction (MI) and coronary revascularization (CR) in type 2 diabetic patients treated with rosiglitazone, metformin, or sulfonylurea.
Using data from a large US insurer, we created propensity-matched cohorts. We identified hospitalizations for MI or CR. We calculated incidence rates and 95% confidence intervals for the outcomes and estimated risks from Cox proportional hazards models.
We identified 26,931 initiators of monotherapy, 4,086 initiators of dual-therapy, and 2,346 initiators of combination with insulin therapy. There was no difference between the risk of the composite outcome with rosiglitazone monotherapy compared to metformin monotherapy (HR 1.07, 95% CI: 0.85, 1.34), and similarly with rosiglitazone monotherapy compared to sulfonylurea monotherapy (HR 0.82, 95% CI: 0.67, 1.02). There was no difference in the risk of outcome with rosiglitazone in combination with insulin therapy compared to other oral antidiabetic agents in combination with insulin (HR 0.88, 95% CI: 0.59, 1.32). Overall, there was little difference in the risk of the composite outcome or of the individual outcomes of MI and CR comparing rosiglitazone therapies to non-rosiglitazone therapies (HR for composite outcome 0.93, 95% CI: 0.80, 1.10).
The results from the monotherapy and the dual-therapy comparisons, though not individually significant, are consistent in suggesting that the risk of cardiovascular outcome events in patients using rosiglitazone may lie between the risks associated with sulfonylureas (higher incidence) and metformin (lower incidence). Copyright © 2007 John Wiley & Sons, Ltd.